VETO.PA · Vetoquinol SA

-

Please sign in to comment on VETO.PA

1 Comment

Admin

4 years ago

Vetoquinol SA is currently in a long term uptrend where the price is trading 12.6% above its 200 day moving average.

From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.

Vetoquinol SA's total revenue sank by 0.0% to $106M since the same quarter in the previous year.

Its net income has dropped by 0.0% to $8M since the same quarter in the previous year.

Finally, its free cash flow fell by 34.2% to $15M since the same quarter in the previous year.

Based on the above factors, Vetoquinol SA gets an overall score of 2/5.

Exchange	PA
CurrencyCode	EUR
ISIN	FR0004186856
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Dividend Yield	1.0%
Beta	0.88
Market Cap	909M
PE Ratio	19.25
Target Price	93.7143

ABOUT

Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

VETO.PA · Vetoquinol SA

-

Vetoquinol SA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Vetoquinol SA using a moving average strategy